Jade Biosciences, Inc. (JBIO) Stock Ticker
JBIO right now
Market factors today
Unlock the full JBIO picture
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
JBIO stock facts
| Ticker symbol | JBIO |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $877.6M |
| CEO | Tom Frohlich |
| Employees | 55 |
| Headquarters | Waltham, MA, US |
| IPO date | 2021-06-30 |
| Website | jadebiosciences.com |
What you can see for JBIO on Tickr
Live JBIO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the JBIO report.
Rankings
FAQ
What is the ticker symbol for Jade Biosciences, Inc.?
The ticker symbol for Jade Biosciences, Inc. is JBIO, listed on the NASDAQ Global Market.
What is JBIO?
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage.…